Vestal Point Capital’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
Other funds holding TSHA
SL
Vestal Point Capital's TSHA Position: Q3 2026 in Review
Vestal Point Capital reduced its Taysha Gene Therapies (TSHA) stake by 7.1% in Q3 2026, selling an estimated $7.9M and leaving 18,045,000 shares worth $87.9M. The position accounts for 2.27% of the portfolio, ranked #15.
Vestal Point Capital first reported a position in TSHA in Q2 2025 and has held it in 6 quarters since. The position peaked at $132M in Q2 2026. 205 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.
- Vestal Point Capital held 18,045,000 shares of Taysha Gene Therapies worth $87.9M as of Q3 2026.
- Vestal Point Capital sold 1,370,000 Taysha Gene Therapies shares in Q3 2026, an estimated $7.9M.
- Taysha Gene Therapies made up 2.27% of Vestal Point Capital's portfolio in Q3 2026, its #15 holding.
- Vestal Point Capital first reported a position in Taysha Gene Therapies in Q2 2025 and has held it in 6 quarters since.
- Vestal Point Capital's Taysha Gene Therapies position peaked at $132M in Q2 2026.
- 205 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.
Based on Vestal Point Capital's 13F filing for Q3 2026, filed 16 Nov 2026.